Objective: Soluble CD163 (sCD163) is a biomarker involved in inflammation. There is little data on the prognostic utility of sCD163 in coronavirus disease-2019 (COVID-19). This study investigated the relationship between serum sCD163 and the prognosis of COVID-19. Methods: A total of 79 hospitalized patients diagnosed with COVID-19 were included in this retrospective study. Patients were divided into two groups as survivors and non-survivors. The clinical characteristics, serum sCD163 level, and other laboratory data of patients were compared between the groups. Results: Forty-two (53.2%) of the 79 cases were male. The mean age was 70.4±12 years in the non-survivor group and 64.2±14 years in the survivor group (p=0.079). Serum sCD163, prothrombin time, and lactate were significantly higher in non-survivors than in survivors (p=0.023, p=0.015, p=0.018, respectively). The optimum cutoff value of serum sCD163 by receiver operating curve analysis was 2.92 ng/mL, resulting in 74% sensitivity and 52% specificity for predicting mortality (area under the curve: 0.620, 95% confidence interval: 0.481-0.759, p=0.048). Serum sCD163≥2.92 ng/mL was associated with 4.3 times higher mortality risk as assessed by logistic regression analysis (p=0.014). Conclusion: sCD163 is an independent predictor of mortality in COVID-19 positive patients who have a fatal course of the disease.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Benzer Makaleler | Yazar | # |
---|
Makale | Yazar | # |
---|